FDA Approves TOFACITINIB — Somerset Therapeutics, LLC

# FDA Approves Generic Tofacitinib; Somerset Therapeutics Enters Competitive JAK Inhibitor Market Somerset Therapeutics, LLC has received FDA approval for its generic tofacitinib citrate oral formulation, marking a significant expansion in the competitive landscape for JAK inhibitors used in rheumatoid arthritis and other inflammatory conditions. The approval is expected to intensify pricing pressure on the branded Xeljanz and accelerate patient access to the therapy through lower-cost alternatives.